assignment
Not Recruiting

Phase 2 Randomized Study of Ceralasertib and Ceralasertib Plus Durvalumab in Unresectable or Advanced Melanoma with PD-(L)1 Inhibitor Resistance

Trial ID
2024-512378-91-00
Protocol
D533AC00001

Register record, history and transparency: CTIS.eu

Trial statistics

science
5
test molecules
location_city
25
research sites
public
6
countries
medical_information
1
disease
person_search
32
investigators
handshake
1
vendor

Diseases & Conditions

Malignant melanoma

Objectives

The primary objective of this study is to estimate the effectiveness of **ceralasertib** monotherapy and ceralasertib in combination with **durvalumab** by assessing the objective response rate (ORR) in patients with unresectable or advanced melanoma who exhibit primary or secondary resistance to a PD-(L)1 inhibitor. This is clinically relevant as it addresses the challenge of treatment resistance in advanced melanoma, potentially offering new therapeutic options for this patient population. Additionally, a biopsy sub-study aims to assess changes in CD8+ T cell infiltration of tumors induced by ceralasertib monotherapy, which could provide insights into the immunomodulatory effects of the treatment.

Secondary objectives include estimating the effectiveness of ceralasertib monotherapy and ceralasertib plus durvalumab by assessing:

  • Duration of Response (DoR)
  • Time to Objective Response (TTR)
  • Change in target lesion tumor size
  • Progression-Free Survival (PFS)
  • Overall Survival (OS)
  • Pharmacokinetics (PK) of ceralasertib alone and in combination with durvalumab
Furthermore, a biopsy sub-study will evaluate the effectiveness of ceralasertib plus durvalumab by assessing ORR, DoR, TTR, change in tumor size, PFS, and OS. Additional biopsy sub-studies aim to collect tumor tissue samples for the analysis of tumor biomarkers that change following treatment with ceralasertib and to assess changes in the proliferation of carcinoma and/or immune cells within tumors induced by ceralasertib monotherapy.

Participants

The clinical trial involves a total of **86 participants** diagnosed with **unresectable or advanced melanoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected based on a confirmed diagnosis of unresectable or metastatic melanoma of cutaneous, acral, or mucosal subtype, and must have received at least one prior immunotherapy treatment. The trial includes individuals with primary or secondary resistance to a PD-(L)1 inhibitor. The study population is characterized by a requirement for measurable disease by RECIST 1.1 criteria and known BRAF V600E or V600K mutation status at screening. Participants are required to provide archival and fresh tumor samples, and those in the biopsy sub-study must consent to three mandatory tumor biopsies. The trial does not exclude vulnerable populations, indicating a broad inclusion of participants with varying health statuses. Lifestyle factors such as diet and physical activity are not specified in the trial data provided.

Plans and Procedures

The clinical trial is designed as a **randomized**, open-label, Phase 2 study to evaluate the efficacy of **ceralasertib** monotherapy and ceralasertib in combination with **durvalumab** in patients with unresectable or advanced melanoma. The primary objective is to assess the objective response rate (ORR) in patients with primary or secondary resistance to PD-(L)1 inhibition. The trial is expected to run until April 30, 2026, with recruitment having started on August 4, 2022. Participants will be involved in the study for a maximum treatment period of 22 weeks.

The trial includes several key visits: an initial screening visit to confirm eligibility, regular follow-up visits to monitor treatment response and safety, and an end-of-study visit to assess final outcomes. The inclusion criteria require participants to have a confirmed diagnosis of unresectable or metastatic melanoma, measurable disease by RECIST 1.1, and prior treatment with at least one immunotherapy regimen. Exclusion criteria are not specified in the provided data.

Participants will be randomly assigned to one of the treatment arms, either receiving ceralasertib alone or in combination with durvalumab. The study will involve regular assessments, including tumor biopsies to evaluate CD8+ T cell infiltration and other biomarkers. The primary endpoint is the ORR for each treatment arm, with secondary endpoints including duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS).

Participants may be withdrawn from the study if they experience unacceptable toxicity, withdraw consent, or if the investigator deems it in their best interest. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

Treatment

The clinical trial involves the administration of several treatments, including both experimental and non-experimental medications. **Durvalumab**, marketed as IMFINZI, is a **concentrate for solution for infusion**. It is administered intravenously at a concentration of 50 mg/mL. The maximum daily dose is 1500 mg, with a total maximum dose of 33,000 mg over a treatment period of 22 weeks. Durvalumab is a protein-based therapeutic agent developed by AstraZeneca AB, and it is not a pediatric formulation.

**Infliximab**, marketed as Inflectra, is provided as a **powder for concentrate for solution for infusion**. This medication is also administered intravenously, with a dosage of 5 mg/kg and a total maximum dose of 15 mg/kg over the same 22-week period. Infliximab is a protein-based therapeutic agent produced by Pfizer Europe MA EEIG.

**Ceralasertib**, also known by its sponsor product code AZD6738, is an experimental medication provided in the form of a **film-coated tablet**. It is administered orally, with a maximum daily dose of 480 mg and a total maximum dose of 73,920 mg over 22 weeks. Ceralasertib is a chemical-based agent developed by AstraZeneca AB. It is used both as a monotherapy and in combination with durvalumab in this trial.

**Mycophenolate mofetil** is provided in the form of **250 mg capsules**. It is administered orally with a maximum daily dose of 2 g. This medication is an immunosuppressive agent produced by Accord Healthcare Limited. It is used as a comparator treatment in the study.

Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the prescribed treatment regimens. The trial aims to evaluate the effectiveness of ceralasertib monotherapy and its combination with durvalumab in patients with unresectable or advanced melanoma, particularly those with primary or secondary resistance to PD-(L)1 inhibitors.

Efficacy

The efficacy of the clinical trial will be assessed primarily through the estimation of the **Objective Response Rate (ORR)** for each experimental treatment arm. This will involve comparing the ORR between the two treatment arms to determine the odds ratio. Additionally, the biopsy sub-study will evaluate CD8+ T cell infiltration in tumors at baseline, during treatment, and after treatment cessation. Secondary endpoints include median and landmark Duration of Response (DoR) estimates at 6, 9, 12, 15, and 18 months, as well as median Time to Response (TTR) and the proportion of patients with a response at the first scheduled tumor assessment. The percentage change from baseline in target lesion tumor size at week 16 and the best percentage change from baseline will also be measured.

Further secondary endpoints include median and landmark Progression-Free Survival (PFS) at 3, 6, 9, and 12 months, and median and landmark Overall Survival (OS) at 6, 9, 12, and 18 months, with hazard ratios comparing the two treatment arms. The concentration of ceralasertib in plasma will be monitored, focusing on peak and trough concentrations as data allows, using sparse sampling. The biopsy sub-study will also assess pre-treatment presence and changes in PD-L1 and pRAD50, as well as the proliferation of carcinoma and immune cells, including CD8+ T cells, using the Ki67+ marker in baseline, on-treatment, and off-treatment tumor biopsies. These assessments will be conducted using the investigator's assessment of tumor response per RECIST 1.1 criteria.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Patient must have a histologically or cytologically confirmed diagnosis of unresectable or metastatic melanoma of cutaneous, acral or mucosal subtype
  • Availability of an archival tumour sample and a fresh tumour biopsy taken at screening.
  • Patient must have received at least 1 prior immunotherapy (anti-PD- (L)1 ± anti-CTLA-4) for a minimum of 6 weeks and no more than 2 prior regimens in the metastatic setting. Patients must have confirmed progression during treatment with a PD-(L)1 inhibitor +/- a CTLA-4 inhibitor.
  • No intervening treatment eg, investigational therapy is permitted between the anti-PD-(L)1 therapy and study treatment
  • BRAF V600E or V600K mutation status must be known at screening
  • Measurable disease by RECIST 1.1.
  • Biopsy Sub-Study: Consent to the provision of 3 mandatory tumour biopsies.
  • Biopsy Sub-Study: Have at least 1 tumour lesion medically accessible for 3 biopsies at baseline, on ceralasertib treatment and off ceralasertib treatment. Accessible lesions are defined as tumour lesions which are amenable to biopsy, unless clinically contraindicated or the patient has withdrawn consent. It is preferable that the same lesion is used for each biopsy, but if this is not possible, a patient may enrol if they have more than 1 lesion that is suitable for biopsy from the same tissue type eg, 3 cutaneous lesions
  • Biopsy Sub-Study: Lesions used for biopsy should be different from those used as RECIST lesions, unless there are no other lesions suitable for biopsy
  • Biopsy Sub-Study: Lesions used for biopsy may have received prior radiation therapy only if there is documented evidence of progression in the lesion after radiation treatment
cancel

Exclusion Criteria

  • Patients must not have experienced a toxicity that led to permanent discontinuation of prior CPI treatment.
  • Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow a formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of study treatment
  • Uveal melanoma
  • Must not have experienced a Grade ≥ 3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy.
  • Active or prior documented autoimmune or inflammatory disorders (including, but not limited to inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, irritable bowel disease, Wegner syndrome, Hashimoto syndrome, hyperthyroidism, Sjogren's syndrome, glomerulonephritis, multiple sclerosis, vasculitis, heumatoid arthritis, idiopathic pulmonary fibrosis, pneumonitis, organising pneumonia, hepatitis, sarcoidosis, active tuberculosis) within the past 3 years
  • Inadequate bone marrow and impaired hepatic or renal function.
  • Biopsy Sub-Study: Patients must comply with the exclusion criteria described for the main study
  • Biopsy Sub-Study: Patients with evidence of bleeding disease deemed unsafe for serial biopsies

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Belgium BelgiumNot Recruiting04 Aug 20229
France FranceNot Recruiting04 Aug 202230
Germany GermanyNot Recruiting04 Aug 202251
Italy ItalyNot Recruiting04 Aug 202261
Poland PolandNot Recruiting04 Aug 202235
Spain SpainNot Recruiting04 Aug 202219

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Mycophenolate Mofetil 250 mg Capsules
OtherCAPSULESORAL222PRD391889
IMFINZI 50 mg/mL concentrate for solution for infusion.
TestCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS150022PRD6651398
Inflectra 100 mg powder for concentrate for solution for infusion
OtherPOWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS USE522PRD6483369
Ceralasertib
TestFILM COATED TABLETORAL48022PRD10810116

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Infliximab
107 trials

Also investigated for

Non-small cell lung cancer 17Colitis ulcerative 14Crohn's disease 11Hepatocellular carcinoma 9
vaccines
Ceralasertib
8 trials

Also investigated for

Non-small cell lung cancer metastatic 2Breast cancer recurrent 1Breast cancer stage III 1Breast cancer stage IV 1
vaccines
Durvalumab
172 trials

Also investigated for

Non-small cell lung cancer 33Hepatocellular carcinoma 21Non-small cell lung cancer stage III 18Cholangiocarcinoma 10
vaccines
Mycophenolate Mofetil
122 trials

Also investigated for

Non-small cell lung cancer 17Renal transplant 14Hepatocellular carcinoma 9Lupus nephritis 8